


Pharmaceuticals & Biotechnology | Small Cap
Jeena Sikho Lifecare Ltd shows a mixed financial performance. The company demonstrates strong profitability, driven by impressive gross profit and operating margins, return on capital employed, and return on equity. Its solvency position is also strong, indicating a low reliance on debt. However, liquidity is a concern, as the company struggles to maintain adequate levels of current assets to cover short-term liabilities. Efficiency ratios are also mixed, with some areas needing improvements. The company faced significant revenue decline recently, impacting overall growth. While interest coverage is adequate, dividend coverage is weak. The financial ratios reflect low earnings and book value per share, offset partly by significant capital expenditure. Overall, the company excels in profitability and solvency but needs to address its liquidity and growth challenges to ensure long-term financial stability.
Jeena Sikho Lifecare Ltd shows a mixed financial performance. The company demonstrates strong profitability, driven by impressive gross profit and operating margins, return on capital employed, and return on equity. Its solvency position is also strong, indicating a low reliance on debt. However, liquidity is a concern, as the company struggles to maintain adequate levels of current assets to cover short-term liabilities. Efficiency ratios are also mixed, with some areas needing improvements. The company faced significant revenue decline recently, impacting overall growth. While interest coverage is adequate, dividend coverage is weak. The financial ratios reflect low earnings and book value per share, offset partly by significant capital expenditure. Overall, the company excels in profitability and solvency but needs to address its liquidity and growth challenges to ensure long-term financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
33.81
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
33.85
P/B RATIO
16.07
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
9.20
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
20.64
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹604.25 as on Aug 6, 2026.
The company's growth ratios reflect decline in key areas. There is a strong growth in net income, which is a positive sign. The challenges in revenue, operating profit, EPS, and asset growth indicate potential difficulties in expanding its operations and market presence. A focus on sustainable growth strategies is essential for long-term success.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | 39.46 | 70.79 | ||
| Operating Profit Growth Rate | 155.56 | 147.52 | ||
| Earnings Per Share (EPS) Growth | 121.14 | 177.6 | ||
| Asset Growth Rate | 143.55 | 60.86 | ||
| Net Income Growth Rate | 209.09 | 177.5 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 21.40 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 9 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 10 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 59.39 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
| 21 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Concall Report⬤7th Nov 25
Q2 FY26 Earnings Conference Call
BULLISH SENTIMENT